newsfilter
← Latest News
GlobeNewswire·

Moleculin Announces Completion of Treatment for the 45 Patients in Pivotal "MIRACLE" Phase 3 AML Trial on Pace for Q1 2026

Continues to drive enrollment with increase to 78% now consentedBlinded response activity tracking within expected range Consented subjects now across seven countries supporting the expansion of the MIRACLE trial